US Patent No: 7,070,996

Number of patents in Portfolio can not be more than 2000

Production of cultured human mast cells and basophils for high throughput small molecule drug discovery

ALSO PUBLISHED AS: 20030077824

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Provided are methods for producing and screening proliferated populations of CD34-negative progenitor cells, mucosal mast cells, connective tissue-type mast cells and basophil cells. The methods generate uniform proliferated populations of cells. The proliferated populations contain a uniform population of a size suitable for use in high throughput screening methods, for example, screening for agents that alter exocytosis. The invention includes screening the proliferated populations with at least one candidate bioactive agent, and evaluating the cells to detect a cell with an altered phenotype. The invention also includes isolating a candidate bioactive agent that causes the altered phenotype. Additionally, cells formed according to the described methods are also encompassed by the invention.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
RIGEL PHARMACEUTICALS, INC.SOUTH SAN FRANCISCO, CA316

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Rossi, Alexander B San Francisco, CA 26 593

Cited Art Landscape

Patent Info (Count) # Cites Year
 
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (1)
6,225,044 Method for gene transfer into cells activated from a quiescent state 4 1999
 
CELLDEX THERAPEUTICS, INC. (3)
5,554,512 Ligands for flt3 receptors 30 1994
5,843,423 Methods of stimulating hematopoietic cells with flt3-ligand 55 1997
6,190,655 Methods of using Flt-3 ligand for exogenous gene transfer 15 1998
 
NORTHWESTERN UNIVERSITY (1)
6,261,841 Compositions, kits, and methods for modulating survival and differentiation of multi-potential hematopoietic progenitor cells 3 2000
 
DANA-FARBER CANCER INSTITUTE, INC. (1)
4,559,310 Assay methods and systems utilizing mast cell clones 14 1983
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
RIGEL PHARMACEUTICALS, INC. (12)
7,557,210 2,4-pyrimidinediamine compounds and their uses 47 2003
8,178,671 Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds 11 2004
* 2005/0234,049 Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds 105 2004
7,521,560 2-substituted quinoline compounds and their uses 0 2005
7,435,814 2,4-Pyrimidinediamine compounds and their uses 28 2005
7,582,648 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds 43 2006
7,452,879 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds 48 2006
7,659,280 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases 6 2007
7,655,797 Intermediates for making 2,4-pyrimidinediamine compounds 23 2008
7,803,939 2,4-pyrimidinediamine compounds and their uses 21 2008
8,334,296 2,4-pyrimidinediamine compounds and their uses 3 2008
8,314,093 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases 0 2009
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 4, 2018
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00